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This article explores an alternative understanding of how psychiatric drugs works that 
is referred to as the drug-centred model of drug action. Unlike the current disease-
centred model, which suggests that psychiatric drugs work by correcting an 
underlying brain abnormality, the drug-centred model emphasises how psychiatric 
drugs affect mental states and behaviour by modifying normal brain processes. The 
alterations produced may impact on the emotional and behavioural problems that 
constitute the symptoms of mental disorders. 
Methods: 
Arguments are put forward that justify the consideration of the drug-centred model. 
The research necessary to support the prescription of drugs according to such a model 
is explored. 
Results:  
Evidence from neurochemistry and comparative drug trials do not confirm the 
disease-centred model of drug action. Since psychiatric drugs are recognised to have 
mind and behaviour-altering properties, the drug-centred model constitutes a plausible 
alternative. The drug-centred model suggests research is needed to identify all the 
alterations produced by various sorts of drugs, both acute and long-term, and how 
these might interact with the symptoms and problems associated with different mental 
disorders. This requires detailed animal and volunteer studies and data from patients 
prescribed drug treatment long-term, along with placebo-controlled and comparative 
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trials that look at the overall impact of drug-induced alterations on well-being and 
functioning as well as symptoms. Research is also needed on alternative ways of 
fulfilling the function of drug treatment. The moral aspect of using drugs to modify 
behaviour rather than treat disease needs honest and transparent consideration. 
Conclusions:  
It is hoped this discussion will encourage the psychiatric and pharmaceutical research 
community to provide more of the information that is required to use psychiatric 
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Models of drug action 
Psychiatric drugs are currently understood to exert their beneficial effects by helping 
to normalise an underlying brain abnormality that is thought to be responsible for 
producing the symptoms of a particular mental disorder.  Thus antipsychotics are 
believed to reverse the pathology that produces psychotic symptoms or schizophrenia, 
antidepressants are believed to act on the biological processes that produce symptoms 
of depression, mood stabilisers are thought to help normalise the processes that 
produce abnormal mood swings and so on. The underlying pathology is sometimes 
proposed to consist of an imbalance in neurotransmitters or neurocircuitry (Hyman & 
Nestler, 1996), but often it is not specified. This view of drug action is promoted by 
the pharmaceutical industry, whose websites frequently refer to the idea that 
psychiatric drugs work by “balancing the chemicals naturally found in the brain” (Eli 
Lilly, 2006), and literature produced by professional organisations like the United 
Kingdom’s Royal College of Psychiatrists and the American Psychiatric Association 
(American Psychiatric Association, 2005; Royal College of Psychiatrists, 2009).  
       Assumptions about drug action are rarely articulated, but this view can be set out 
in what I have called the ‘disease-centred’ model or theory of drug action (Table).       
The disease-centred model has been imported from general medicine, where most 
modern drugs are correctly understood in this way. Although most medical treatments 
do not reverse the original disease process, they act on the physiological processes 
that produce symptoms. Thus, beta agonists help reverse airways obstruction in 
asthma and chemotherapeutic agents counteract the abnormal cell division that occurs 
in cancer. Analgaesics such as paracetamol and non-steroidal anti-inflammatory drugs 
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also work in a disease-centred manner by acting on the physiological processes that 
produce pain. 
     The disease centred model assumes that drugs exert their relevant effects only in 
people with a specific bodily abnormality or disease. The effects of drugs can 
therefore be meaningfully divided into the therapeutic effects, which are the effects on 
the disease process, and other effects, which are referred to as “side effects”. The 
therapeutic effects will only be apparent in people who have the underlying pathology. 
     An alternative explanation for the effects of drugs in psychiatric disorders can be 
called the ‘drug-centred’ model of drug action. This model highlights that psychiatric 
drugs can be considered to be ‘psychoactive’ drugs in the sense that they are  
substances which cross the blood brain barrier and affect brain functioning, thereby 
producing  characteristic mental as well as physical alterations in anyone who ingests 
them (Moncrieff, 2008). There is no essential distinction, according to this view, 
between drugs used for psychiatric treatment and recreational psychoactive drugs like 
alcohol and cocaine. All psychoactive drugs produce altered physical and mental 
states which can influence the way people think, feel and act, with different sorts of 
substances having different sorts of effects. The effects of recreational drugs are 
experienced as desirable by at least some people, but some drugs produce mental and 
physical changes that are generally disliked (e.g. antipsychotics and lithium). The 
drug-centred model suggests that it is these psychoactive properties that explain the 
changes seen when drugs are given to people with psychiatric problems. Drugs like 
benzodiazepines and alcohol, for example, reduce arousal and induce a usually 
pleasant state of calmness and relaxation. This state may be experienced as a relief for 
someone who is intensely anxious or agitated. But taking a drug like this does not 
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return the individual to ‘normal’, or to their pre-symptom state. It is simply that the 
drug-induced state may be preferable to intense anxiety.   
     There are few examples of drugs working in a drug-centred way in modern 
medicine, but historically the psychoactive effects of alcohol were an important part 
of its analgaesic properties. Opiates also work partly through a drug-centred 
mechanism. Although they reduce pain directly by inhibiting the conduction of pain 
stimuli (a disease-centred action), they are psychoactive drugs which induce an 
artificial state of emotional indifference and detachment. People who have taken 
opiates for pain often say that they still have some pain, but do not care about it 
anymore.  
    According to a drug-centred model, therefore, psychiatric drugs produce a global 
state characterised by a range of physiological and psychological alterations. These 
alterations are likely to interact with the symptoms of mental disorders in ways that 
may sometimes be beneficial. 
 
 
Evidence on drug action   
Elsewhere I have documented how the disease-centred model of drug action evolved 
because of the vested professional, commercial and political interests it supported 
rather than the strength of scientific evidence. In fact, there is little evidence to 
suggest that any class of psychiatric drugs acts according to the disease-centred model 
(Moncrieff, 2008; Moncrieff & Cohen, 2005). Placebo controlled trials do not 
distinguish whether drugs have a disease-centred or drug-centred action. They only 
indicate that drugs have different effects from an inert substance; the placebo.  
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    Hypotheses about the neurochemical origins of psychiatric disorders that might 
support the disease-centred model of drug action have not been substantiated. 
Antipsychotic drugs affect dopamine, among other neurotransmitters, but evidence for 
perturbations in the dopamine system that are specific to schizophrenia or psychosis, 
and independent of prior drug treatment, remains weak (Kendler & Schaffner, 2011; 
Moncrieff, 2009). Studies of the dopamine content of post-mortem brains and 
dopamine metabolites are negative, for example. The increased concentration of 
dopamine D2 receptors, which was identified in brains of people with schizophrenia, 
transpired to be due to the effects of drug treatment. Recent studies report that indirect 
measures of dopamine activity are sometimes abnormal in people with acute 
psychosis. However, we know that dopamine is implicated in a range of functions 
including arousal, movement and stress that will confound its relations with any 
specific psychiatric disorder (Moncrieff, 2009). Moreover, the total number of drug 
naïve participants in these studies is small.     
     Evidence on whether depression is caused by abnormalities of brain chemicals that 
might be reversed by drugs is even more contradictory. Studies of serotonin receptors, 
for example, show increased levels in depression in some studies, decreased levels in 
other studies and no difference in some (Moncrieff & Cohen, 2006). There are claims 
that tryptophan depletion produces depression, but the research has involved people 
who had been previously treated with SSRIs, and studies with volunteers show no 
effects (Murphy, Smith, Cowen, Robbins & Sahakian, 2002). In 2001, the leading 
American textbook of psychiatry concluded that “studies of serotonin function in 
depression suggest both hypofunction and hyperfunction”  (Dubovsky, Davies & 
Dubovsky, 2001). In 2013, psychopharmacologist, Stephen Stahl concluded: “direct 
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evidence for the monoamine hypothesis [of depression and mood disorders] is still 
largely lacking” (Stahl, 2013)(P 262). 
    If the disease-centred model cannot be definitively supported, the drug-centred 
model of drug action has to be accepted as a possibility. No one disputes that 
psychiatric drugs alter normal mental functions, even if these ‘psychoactive’ effects 
have attracted little attention. It would be implausible to think these effects have no 
impact on the thoughts and behaviours that constitute the criteria for mental disorders.  
  
Using drugs according to a drug centred model  
The drug-centred model suggests that drugs with psychoactive effects may affect the 
symptoms of mental disorders by virtue of their effects on mental states and 
behaviour in general. It is possible that in some situations these interactions will be 
beneficial, at least from certain points of view. In other words, the behavioural 
adjustment produced by a drug may be judged to be preferable to the manifestations 
of the mental disorder (Breggin, 2008).  
    All sorts of drugs with sedative effects, for example, may be helpful in people with 
insomnia, anxiety and the distress or behavioural disturbance that accompanies acute 
psychosis and other situations. Antipsychotics produce a specific state of neurological 
inhibition, characterised by cognitive slowing, reduced initiative and motivation and 
emotional restriction that is not simply attributable to their (mostly) sedative effects 
(Breggin, 2008; Moncrieff, Cohen & Mason, 2009). These effects are likely to reduce 
the intensity of emotional distress and psychotic thoughts, but may also impair global 
functioning. 
    Tricyclic antidepressants are strongly sedating which suggests they might be useful 
for symptoms of anxiety and insomnia across different disorders. SSRI 
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antidepressants have more subtle psychoactive effects and are not profoundly sedating. 
They may produce a state of emotional restriction which may reduce the intensity or 
salience of emotions. Whether these effects are really useful, whether they outweigh 
the negative aspects of taking mind and body modifying chemicals, and whether they 
are superior to pharmacological and non-pharmacological alternatives still needs to be 
established, however.  
 
 
Research based on the drug centred model  
In order to use and recommend drugs according to the drug centred model, and to 
avoid iatrogenic harm, we need a whole body of research that has not yet been 
conducted due to the dominance of the disease-centred model over 
psychopharmacological research. We need more comprehensive data about the 
changes that drugs produce in mental and physical states, and then we need research 
to explore how those changes might interact with the manifestations of mental health 
problems and impact on the wider lives of people taking them. Crucially we need data 
that matches the duration of time for which people typically take these drugs. We also 
need to consider the moral aspects of using drugs that modify emotional states and 
behaviour.  
1. Acute psychoactive and physical effects 
Detailed studies with animals and volunteers are needed to establish the acute 
alterations different drugs produce. Animal studies need to measure changes in 
spontaneous behaviour and tests of cognitive performance. Volunteer studies can 
provide additional information about the subjective alterations produced by particular 
drugs including changes in emotions, sensations and cognitive experiences. These 
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alterations need to be reported in descriptive, phenomenological terms that can 
capture the unusual and often unfamiliar nature of drug-induced states, just as early 
users described the experience of taking psychedelic drugs (Huxley, 1954). Human 
volunteers should also be asked to reflect on the experience once the drug’s effects 
have worn off, since it may be difficult to articulate this fully while under the 
influence of the substance. Despite the fact that volunteer studies are required as part 
of drug-licensing procedures, this sort of rich and detailed information has not 
traditionally been considered of interest. Only one recent scientific study conducted in 
the 1990s compared results of psychological tests and subjective experiences in 
volunteers randomised to take a single dose of the antipsychotic droperidol, a 
benzodiazepine or a placebo. Participants who took the antipsychotic could only 
describe certain aspects of the drug experience after the effects had worn off (Healy & 
Farquhar, 1998).   
    Psychoactive drugs also produce physical or bodily changes, which may be linked 
with mental changes. Indeed, these drugs are best understood as producing altered 
global states that have both physical and mental components.  The sedation produced 
by benzodiazepines, and the stimulation produced by stimulants, for example, are 
both simultaneously physical and mental experiences. The sedation and emotional 
indifference produced by antipsychotics like olanzapine may be related to their 
metabolic effects (Moncrieff et al., 2009). Monitoring how drugs affect different 
bodily systems is important to understand the full nature of a drug’s effects and to 
explore correlations between physical changes and mental alterations.   
 
2. Long-term changes 
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Long-term use of a drug has both predictable and unpredictable effects on the body. 
The alterations that occur if a drug is taken repeatedly may be reduced, the 
phenomena known as tolerance, or alternatively enhanced, which is known as 
sensitisation. Tolerance appears to be the more common of these scenarios, due to 
bodily adaptations that counteract some of a drug’s effects, but the phenomena have 
not been adequately investigated for psychiatric drugs (as opposed to recreational 
drugs) and mechanisms remain unclear (Li, 2016). However, some studies suggest 
that olanzapine and haloperidol progressively lose their behavioural effects in animals, 
which is reflected in adaptations of the dopamine system (Samaha, Seeman, Stewart, 
Rajabi & Kapur, 2007). Tolerance to benzodiazepine effects is also recognised, 
although the precise mechanisms is not known (Vinkers & Olivier, 2012).  
     Psychiatric medications are usually prescribed for long periods of time, and 
therefore it is essential to have good information about all the potential alterations and 
complications that occur with long-term treatment in order to make judgments about 
the cost-benefit ratio of using a particular drug. A host of physical complications are 
documented for every class of drug, but there is often little information about the 
prevalence, severity, reversibility and underlying mechanism of such effects. 
Moreover, less tangible effects are often over-looked in the mainstream literature, 
even when they are widely reported by users such as the emotion-numbing effects of 
antipsychotics and antidepressants, and post SSRI sexual dysfunction.  
    The effects of long-term treatment have been under-researched for a number of 
reasons. Most obvious are the difficulties of conducting long-term studies in animals 
or volunteers. Studies with patients taking long-term medication are sometimes 
thought to be unreliable because of the difficulty of distinguishing some drug-induced 
effects from symptoms of the underlying conditions. The disease-centred model, 
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moreover, focuses attention on a drug’s effects on the presumed disease process, with 
other effects relegated to the status of ‘side effects’.  These might be elicited using a 
single list, but are rarely considered worthy of detailed attention. These difficulties 
can result in delayed recognition of serious and sometimes irreversible adverse effects, 
which is illustrated by the history of tardive dyskinesia (Moncrieff, 2013) and more 
recently by the case of post SSRI sexual dysfunction (Bahrick, 2008).  
      Again, animal studies are required to identify changes in animal behaviour and 
performance following long-term treatment, as well as bodily changes. The 
importance of such studies has been underlined recently by the identification of brain 
volume reductions in rats and monkeys following long-term antipsychotic 
administration (Dorph-Petersen, Pierri, Perel, Sun, Sampson & Lewis, 2005; Vernon, 
Natesan, Modo & Kapur, 2011), changes which are also apparent in patients (Ho, 
Andreasen, Nopoulos, Arndt, Magnotta & Flaum, 2003).  
    Data also needs to be collected systematically from people who are on long-term 
treatment for mental health problems, given the difficulties of conducting long-term 
volunteer studies. Looking for common themes and consistencies across different 
diagnostic groups will help enhance the validity of such data. As with acute effects, it 
is important to pay attention to the retrospective reflections of people who have 
discontinued medication since people may not be aware of the full effects of 
medication while they are under the influence of it. Although this sort of data has 
been dismissed in the past, several new initiatives have been designed to capture and 
explore patient reports in more detail (RxISK, 2017). A comparative study found such 
sites identify a similar profile of effects as those presented on professionally 
controlled websites but provide richer detail (Hughes & Cohen, 2011).  
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3. Withdrawal effects  
Along with acute alterations and longer term changes, patients and clinicians need to 
know what effects might occur following discontinuation of a drug. It is now widely 
acknowledged that withdrawal effects can occur following cessation of all sorts of 
drugs prescribed for mental health problems. However, there is little preclinical data 
on the prevalence or nature of withdrawal effects. Animal studies that assess 
withdrawal effects should be routine and more comprehensive, and long-term data 
needs to be collected from patients who have discontinued medication. Although 
withdrawal effects are reported in the literature, there remain few studies that set out 
to investigate these effects in a comprehensive and systematic manner. It is also 
important to establish the course of changes following withdrawal. Some patients 
report protracted symptoms following withdrawal of benzodiazepines and 
antidepressants, for example (Fava, Gatti, Belaise, Guidi & Offidani, 2015), and so far 
we are unable to clarify whether withdrawal-related changes normalise over time in 
everyone or not.      
 
4. Neurotransmitter research 
Data on the neurochemical correlates of the behavioural, emotional and cognitive 
changes produced by different drugs is interesting, but the situation is likely to be 
more complex than has so far been presented. It is rarely appreciated that we do not 
have a good understanding of the full functions of any neurotransmitter system, and it 
is likely that their effects are all deeply interconnected.  
    Moreover, most drugs affect a range of neurochemical systems in a variety of ways. 
Although interest has centred on the action of antipsychotic drugs on the dopamine 
and serotonin systems, for example, these drugs also have varying effects on the 
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noradrenergic and histaminergic systems in ways that are likely to be significant in 
the behavioural alterations they produce for some agents.       
    The difficulty of linking specific neurochemicals with manifest behaviour means 
that we have to start, as stressed above, with detailed descriptions of the changes that 
drugs produce in living organisms, both animals and humans. With more 
sophisticated techniques, we may one day be able to link these with specific 
neurochemical processes. Alternatively, it may be the case that the complexity of 
inter-relations between brain states and behaviour will always exceed our ability to 
describe it.  
 
 
5. Interaction of psychoactive effects and mental symptoms 
Once the acute and longer-term alterations produced by a particular drug have been 
established, it is possible to start evaluating how those alterations might interact with 
the symptoms of various mental disorders, and whether any beneficial or desirable 
consequences might result.  
    First, we need to know how the alterations produced by a particular drug affect 
specific symptoms. Is the characteristic state of neuro-suppression produced by 
antipsychotics effective at reducing the intensity of psychotic experiences and the 
disturbed behaviour that often accompanies these, for example? Existing placebo 
controlled trials provide some information about this, but we also need comparative 
trials to demonstrate whether the particular effects of antipsychotics are superior to 
the effects of other drugs with psychoactive effects that might plausibly be useful, 
including other sedative agents like benzodiazepines. Similarly, we might explore 
whether the emotional numbing produced by some antidepressants impacts on 
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depressed mood, anxiety and other symptoms. Again, we need to clarify whether this 
effect is specific to a certain class of drugs, or whether similar effects are obtained 
with other psychoactive agents. 
     The role of placebo effects is important in research based on a drug-centred model 
of drug action, as it is in current research. However, by highlighting the fact that 
psychiatric drugs produce noticeable physical and mental alterations and can therefore 
often be distinguished from an inert placebo, the drug-centred model suggests that use 
of inert placebos may not adequately control for the effects of expectations. Use of 
active placebos may be useful, but unless the alterations experienced with the ‘active 
placebo’ drug are identical to those produced by the agent being investigated, it is not 
possible to rule out expectation effects definitively. There is also the problem that any 
substance that is found to have effects is often designated as a specific agent. A 
variety of psychoactive substances have been found to be modestly superior to an 
inert placebo in depression trials, for example, some of which are designated as 
antidepressants and some are not. The fact that these drugs, including those that are 
considered as antidepressants, have such diverse pharmacological and subjective 
effects suggests they may be acting as amplified placebos, with the psychoactive 
effects facilitating placebo or expectation effects.  
    Second, as well as establishing effects on symptoms, we need to evaluate a drug’s 
effects on other aspects of well-being, using both subjective and objective measures. 
Antipsychotics may have useful effects on psychotic experiences, for example, but 
this may not necessarily translate into overall benefits on quality of life or functioning. 
We know antipsychotics cause impairment of normal neuropsychological functioning 
in animals and volunteers, and that their effects are often experienced as highly 
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disagreeable by users (Moncrieff, 2013). Similarly, the effects of antidepressants and 
other drugs on emotional experience may, or may not, translate into wider benefits.     
    Third, we need to establish whether any identified benefits outweigh adverse 
effects, bearing in mind that some adverse effects take time to emerge. The concepts 
of ‘number needed to treat (NNT) and ‘number needed to harm’ (NNH) represent 
attempts to balance benefits and harms in this way, but we need data that evaluates 
broader outcomes than just symptom improvement, considers all potential adverse 
effects, and compares different types of drugs. 
    All these factors have to be re-evaluated throughout the course of long-term 
treatment if this is to be instituted. Benefits of long-term treatment may be more 
difficult to establish, because of the difficulty of conducting long-term trials and the 
confounding effects of discontinuation-related adverse effects in trials that involve 
discontinuation of established long-term treatment (Moncrieff, 2006). It is vitally 
important, however, that there is more data on long-term costs and benefits of drug 
treatment in view of the fact that long-term treatment is associated with increasing 
burden and probability of adverse effects, and that benefits of drugs may reduce with 
continuing use due to natural remission or improvement of symptoms and 
pharmacological tolerance.  
 
6.  Alternatives to drug treatment 
When we have clarified what drug-induced alterations can achieve, we are in a 
position to compare these with alternative strategies. For this it is important to 
understand the role that drug treatment plays, or is intended to play, in an individual’s 
life. The desired purposes of treatment may be obscured, however, if people believe 
they are taking a drug to treat an underlying disease. Where it appears that drug 
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treatment is desired to reduce the intensity of negative emotions, for example, we 
need data on comparative outcomes of other ways of managing emotions, such as 
exercise, therapy or engaging in new activities. We should also consider how drug 
treatment might hamper the development and utilisation of other strategies for 
regulating emotions, either through direct effects on mental functioning, or by 
suggesting that symptoms are beyond reach by other means. Research into ways of 
helping people to manage psychotic symptoms that might avoid or reduce the need for 
antipsychotic treatment would also be useful.  
 
7. Moral considerations 
The sort of behavioural and emotional changes that drugs produce in different 
situations may be a scientific question, but the drug-centred model highlights that 
there is also a moral question about whether these changes are desirable or not. In 
many cases there is consensus about the value of such changes, but there are 
situations in which different parties evaluate the desirability of drug-induced changes 
differently. The tranquilisation produced by antipsychotics in an acutely aggressive 
patient will be welcomed by onlookers (including staff), for example, but is often 
intensely unpleasant for the patient. Indeed, one study found that recovered patients 
who had experienced rapid tranquilisation said they would have preferred physical 
restraint (Schmeid & Ernst, 1983).   Similarly, the behavioural changes produced by 
long-term antipsychotic treatment may be valued by professionals and carers, but 
disliked by the patient.  
    For this reason it is important to clarify the exact purpose of drug treatment in 
every situation, and whose perspective this purpose serves. Where the primary aim of 
treatment is to make someone’s behaviour less risky or inconvenient to other people, 
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careful moral and legal consideration is required to consider whether this is a 
legitimate goal or not.  
  
Implications for prescribing practice 
A drug-centred approach changes the nature of prescribing, and relationships between 
patients and prescribers. Under the disease-centred model, prescribing is driven 
primarily by diagnosis and theories about the aetiology of the hypothetical underlying 
condition. A drug-centred approach, in contrast, focuses on making judgements about 
when drug-induced mental and behavioural modifications might be useful. Research 
data can inform doctor and patient about the nature of drug-induced effects and their 
impact on various outcomes, but the utility of a drug can only be established by 
assessing each individual’s experience of the whole range of drug-induced effects in 
their own particular situation. It is important to monitor the consequences of drug-
induced alterations on all areas of mental and physical functioning, therefore, 
including the identification of subtle changes (such as changes to emotional 
responsiveness) which may not be routine.  
     The drug-centred model therefore advocates a collaborative form of self-
medication, in which psychiatrists act as reservoirs of information on drugs’ 
psychoactive and physical effects, help to explore the likely overall impact and 
limitations of drug treatment and consider alternative, non-drug based approaches. 
     The drug-centred model can support psychiatrists to rationalise and reduce 
medication when it is ineffective or harmful and to resist inappropriate prescribing. 
Doctors often feel an expectation to prescribe, with some patients viewing a 
prescription as an acknowledgement of their suffering and non-prescription as a 
denial (Pellegino, 1976). The disease-centred model can reinforce these expectations, 
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and patients may become trapped in a cycle of ever increasing medication, because 
the social and personal drivers of symptoms are obscured. The drug-centred model, in 
contrast, offers a way of exploring the potential benefits of drug therapy, without 
raising expectations that it is an essential part of the solution, and of considering non-
pharmacological ways of fulfilling the function that medication is intended to perform.   
      
 
Conclusions 
This article argues that out current assumptions about the nature of drug action are not 
supported by evidence. An alternative, ‘drug-centred’ model of drug action is 
proposed, which changes the way we understand what psychiatric drugs do when they 
are used to treat a mental disorder. The drug-centred model emphasises that 
psychiatric drugs are psychoactive substances that change the normal state of the body 
and brain. The modifications in mental state and behaviour that result may reduce the 
manifestations of some mental disorder, but there is more to consider to evaluate 
whether these changes are worthwhile. The article presents the types of research that 
we need to produce comprehensive information about all the alterations that different 
drugs produce and how these might interact with the symptoms of mental disorders, in 
order to be able to weigh up the pros and cons of using them safely and effectively. 
   Currently much of this information is lacking. Clinicians prescribe drugs for all 
sorts of mental disorders, often for long periods of time, with inadequate knowledge 
about all the consequences of doing so. It is beholden on the psychiatric and 
psychopharmacology research community to investigate the alterations produced by 
psychiatric drugs more thoroughly so that clinicians and patients can make better 
informed decisions about the value of using drug treatment in various situations.  
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Disease centred model Drug centred model 
Drugs correct an abnormal brain state Drugs create an altered physiological state 
Drugs as medical treatments Drugs as psychoactive substances 
Beneficial effects arise from the drugs’ 
action on the underlying disease process 
Beneficial effects are a consequence of being 
in an altered, drug-induced state.  
Therapeutic effects can be distinguished 
from side effects 
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